Pathobiology of cardiac dyssynchrony and resynchronization

Research output: Contribution to journalArticle

Abstract

Cardiac resynchronization therapy (CRT) represents the major new advance for treatment of heart failure since the start of the new millennium. With this therapy, failing hearts with discoordinate contraction due to conduction delay are subjected to biventricular stimulation to "resynchronize" contraction and improve chamber function. Remarkably, CRT was mostly developed and tested in patients first, and the speed at which the concept was translated to an approved clinical therapy was unusually quick. To date, CRT is the only heart failure treatment that can both acutely and chronically improve the systolic pump performance of the failing human heart yet also enhance long-term survival. This situation underscores the importance of understanding how CRT works at the molecular and cellular levels, as these insights might shed light on new approaches to treating heart failure more generally. Over the past 7 years, my laboratory and others at Johns Hopkins have developed novel animal models for addressing this question, and new results are revealing intriguing insights into the mechanisms of CRT. This review, presented on the occasion of the Fourth Annual Douglas P. Zipes Lecture at the 2009 Scientific Sessions of the Heart Rhythm Society, highlights these advances and new directions in CRT research.

Original languageEnglish (US)
Pages (from-to)1660-1665
Number of pages6
JournalHeart Rhythm
Volume6
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Cardiac Resynchronization Therapy
Heart Failure
Treatment Failure
Therapeutics
Animal Models
Survival
Research

Keywords

  • Animal model
  • Apoptosis
  • Beta-adrenergic receptor
  • Calcium
  • Cardiac resynchronization therapy
  • Dyssynchrony
  • Excitation-contraction coupling
  • Heart failure
  • Ion channel
  • Molecular biology
  • Myocyte
  • Stress response kinase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Pathobiology of cardiac dyssynchrony and resynchronization. / Kass, David A.

In: Heart Rhythm, Vol. 6, No. 11, 11.2009, p. 1660-1665.

Research output: Contribution to journalArticle

@article{3fe4ffa0641d4244a891cbd0c23372bf,
title = "Pathobiology of cardiac dyssynchrony and resynchronization",
abstract = "Cardiac resynchronization therapy (CRT) represents the major new advance for treatment of heart failure since the start of the new millennium. With this therapy, failing hearts with discoordinate contraction due to conduction delay are subjected to biventricular stimulation to {"}resynchronize{"} contraction and improve chamber function. Remarkably, CRT was mostly developed and tested in patients first, and the speed at which the concept was translated to an approved clinical therapy was unusually quick. To date, CRT is the only heart failure treatment that can both acutely and chronically improve the systolic pump performance of the failing human heart yet also enhance long-term survival. This situation underscores the importance of understanding how CRT works at the molecular and cellular levels, as these insights might shed light on new approaches to treating heart failure more generally. Over the past 7 years, my laboratory and others at Johns Hopkins have developed novel animal models for addressing this question, and new results are revealing intriguing insights into the mechanisms of CRT. This review, presented on the occasion of the Fourth Annual Douglas P. Zipes Lecture at the 2009 Scientific Sessions of the Heart Rhythm Society, highlights these advances and new directions in CRT research.",
keywords = "Animal model, Apoptosis, Beta-adrenergic receptor, Calcium, Cardiac resynchronization therapy, Dyssynchrony, Excitation-contraction coupling, Heart failure, Ion channel, Molecular biology, Myocyte, Stress response kinase",
author = "Kass, {David A}",
year = "2009",
month = "11",
doi = "10.1016/j.hrthm.2009.08.017",
language = "English (US)",
volume = "6",
pages = "1660--1665",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Pathobiology of cardiac dyssynchrony and resynchronization

AU - Kass, David A

PY - 2009/11

Y1 - 2009/11

N2 - Cardiac resynchronization therapy (CRT) represents the major new advance for treatment of heart failure since the start of the new millennium. With this therapy, failing hearts with discoordinate contraction due to conduction delay are subjected to biventricular stimulation to "resynchronize" contraction and improve chamber function. Remarkably, CRT was mostly developed and tested in patients first, and the speed at which the concept was translated to an approved clinical therapy was unusually quick. To date, CRT is the only heart failure treatment that can both acutely and chronically improve the systolic pump performance of the failing human heart yet also enhance long-term survival. This situation underscores the importance of understanding how CRT works at the molecular and cellular levels, as these insights might shed light on new approaches to treating heart failure more generally. Over the past 7 years, my laboratory and others at Johns Hopkins have developed novel animal models for addressing this question, and new results are revealing intriguing insights into the mechanisms of CRT. This review, presented on the occasion of the Fourth Annual Douglas P. Zipes Lecture at the 2009 Scientific Sessions of the Heart Rhythm Society, highlights these advances and new directions in CRT research.

AB - Cardiac resynchronization therapy (CRT) represents the major new advance for treatment of heart failure since the start of the new millennium. With this therapy, failing hearts with discoordinate contraction due to conduction delay are subjected to biventricular stimulation to "resynchronize" contraction and improve chamber function. Remarkably, CRT was mostly developed and tested in patients first, and the speed at which the concept was translated to an approved clinical therapy was unusually quick. To date, CRT is the only heart failure treatment that can both acutely and chronically improve the systolic pump performance of the failing human heart yet also enhance long-term survival. This situation underscores the importance of understanding how CRT works at the molecular and cellular levels, as these insights might shed light on new approaches to treating heart failure more generally. Over the past 7 years, my laboratory and others at Johns Hopkins have developed novel animal models for addressing this question, and new results are revealing intriguing insights into the mechanisms of CRT. This review, presented on the occasion of the Fourth Annual Douglas P. Zipes Lecture at the 2009 Scientific Sessions of the Heart Rhythm Society, highlights these advances and new directions in CRT research.

KW - Animal model

KW - Apoptosis

KW - Beta-adrenergic receptor

KW - Calcium

KW - Cardiac resynchronization therapy

KW - Dyssynchrony

KW - Excitation-contraction coupling

KW - Heart failure

KW - Ion channel

KW - Molecular biology

KW - Myocyte

KW - Stress response kinase

UR - http://www.scopus.com/inward/record.url?scp=70350488085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350488085&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2009.08.017

DO - 10.1016/j.hrthm.2009.08.017

M3 - Article

VL - 6

SP - 1660

EP - 1665

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 11

ER -